Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of Cidara Therapeutics in a note issued to investors on Wednesday, June 18th. HC Wainwright analyst S. Nik forecasts that the biotechnology company will post earnings of ($2.11) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $41.00 target price on the stock. The consensus estimate for Cidara Therapeutics' current full-year earnings is ($8.74) per share. HC Wainwright also issued estimates for Cidara Therapeutics' Q3 2025 earnings at ($1.40) EPS, Q4 2025 earnings at ($1.46) EPS, FY2025 earnings at ($6.43) EPS, FY2026 earnings at ($6.03) EPS and FY2027 earnings at ($6.53) EPS.
Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($5.45) by $3.79.
A number of other equities research analysts have also weighed in on the stock. Royal Bank Of Canada reissued an "outperform" rating and set a $35.00 target price (up from $31.00) on shares of Cidara Therapeutics in a report on Friday, May 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Cidara Therapeutics in a research note on Tuesday, June 10th. Guggenheim upped their price objective on shares of Cidara Therapeutics from $35.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, May 16th. Needham & Company LLC upped their price objective on shares of Cidara Therapeutics from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. Finally, Citizens Jmp initiated coverage on shares of Cidara Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $46.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $42.86.
Get Our Latest Stock Report on CDTX
Cidara Therapeutics Price Performance
CDTX stock opened at $21.02 on Monday. Cidara Therapeutics has a 1 year low of $10.14 and a 1 year high of $28.42. The stock has a market cap of $263.80 million, a price-to-earnings ratio of -0.71 and a beta of 0.79. The company has a 50 day simple moving average of $22.20 and a 200 day simple moving average of $22.02.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cidara Therapeutics during the 4th quarter valued at $56,000. Point72 Asset Management L.P. acquired a new position in shares of Cidara Therapeutics during the 4th quarter valued at $165,000. American Century Companies Inc. acquired a new position in shares of Cidara Therapeutics during the 1st quarter valued at $224,000. West Michigan Advisors LLC acquired a new position in shares of Cidara Therapeutics during the 1st quarter valued at $291,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Cidara Therapeutics during the 4th quarter valued at $339,000. Institutional investors and hedge funds own 35.82% of the company's stock.
About Cidara Therapeutics
(
Get Free Report)
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cidara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cidara Therapeutics wasn't on the list.
While Cidara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
